Several Asia biotechs this week – including Innocare Pharma Ltd., Akeso Pharmaceuticals Inc., Sanbio Co. Ltd. and Ascletis Pharma Inc. – unveiled the start of new late-stage clinical trials or interim findings from early stage studies.
Daewoong Pharmaceutical Co. Ltd. has described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Several Asia biotechs this week – including Innocare Pharma Ltd., Akeso Pharmaceuticals Inc., Sanbio Co. Ltd. and Ascletis Pharma Inc. – unveiled the start of new late-stage clinical trials or interim findings from early stage studies.
Adcentrx Therapeutics Inc. and Adcentrx Therapeutics Shanghai Co. Ltd. have disclosed antibody-drug conjugates comprising a monoclonal antibody covalently bound to a cytotoxic drug through a linker.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described molecular glue compounds acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer.
Sunshine Lake Pharma Co. Ltd. has disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
The latest patenting from Canan Dagdeviren seeks protection for their wearable, conformable ultrasound breast patch that enables standardized and reproducible image acquisition over the entire breast with less reliance on operator training and applied transducer compression.
Ona Therapeutics SL is accelerating development of its first-in-class antibody-drug conjugate (ADC) therapeutics, targeting novel tumor-specific markers to eliminate hard-to-treat, resistant cancer cells for multiple large solid tumor types.
Solid tumors are difficult to treat due to their heterogeneity and limited blood supply, which restrict the effective delivery of anticancer drugs. Macrophages are abundant in solid tumor tissues and are the only cell type actively infiltrating hypoxic tumor regions, making them a promising option for delivering therapeutic agents directly to tumors.
